Total Payments
$1.1M
2024 Payments
$3,329
Companies
41
Transactions
233
Medicare Patients
1,513
Medicare Billing
$413,010
Payment Breakdown by Category
Research$1.1M (99.2%)
Travel$5,084 (0.5%)
Food & Beverage$3,295 (0.3%)
Consulting$28.86 (0.0%)
Education$8.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.1M | 57 | 99.2% |
| Travel and Lodging | $5,084 | 16 | 0.5% |
| Food and Beverage | $3,295 | 152 | 0.3% |
| Consulting Fee | $28.86 | 7 | 0.0% |
| Education | $8.59 | 1 | 0.0% |
Payments by Type
Research
$1.1M
57 transactions
General
$8,417
176 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| First Wave BioPharma, Inc. | $1.1M | 50 | $0 (2022) |
| Eli Lilly and Company | $5,119 | 1 | $0 (2021) |
| ModernaTX, Inc. | $2,366 | 11 | $0 (2024) |
| ALK-Abello, Inc | $2,022 | 15 | $0 (2019) |
| Supernus Pharmaceuticals, Inc. | $1,764 | 27 | $0 (2018) |
| Kowa Research Institute, Inc. | $1,029 | 5 | $0 (2024) |
| Merck Sharp & Dohme LLC | $734.02 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $403.66 | 4 | $0 (2024) |
| KVK-Tech, Inc. | $188.29 | 34 | $0 (2022) |
| AstraZeneca UK Limited | $165.03 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,329 | 20 | ModernaTX, Inc. ($1,270) |
| 2023 | $1,136 | 5 | ModernaTX, Inc. ($1,096) |
| 2022 | $866,101 | 46 | First Wave BioPharma, Inc. ($865,648) |
| 2021 | $205,109 | 38 | First Wave BioPharma, Inc. ($199,730) |
| 2020 | $53.43 | 6 | GlaxoSmithKline, LLC. ($24.29) |
| 2019 | $1,661 | 43 | ALK-Abello, Inc ($1,298) |
| 2018 | $460.86 | 51 | Supernus Pharmaceuticals, Inc. ($125.60) |
| 2017 | $2,631 | 24 | Supernus Pharmaceuticals, Inc. ($1,638) |
All Payment Transactions
233 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $234.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $234.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $120.64 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/18/2024 | Kowa Research Institute, Inc. | — | Travel and Lodging | In-kind items and services | $200.00 | General |
| 09/18/2024 | Kowa Research Institute, Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 09/18/2024 | Kowa Research Institute, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 09/18/2024 | Kowa Research Institute, Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $458.95 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $265.53 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $240.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $81.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/13/2024 | Kowa Research Institute, Inc. | — | Travel and Lodging | In-kind items and services | $729.22 | General |
| 04/20/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $203.81 | General |
| 04/20/2024 | Novartis Pharmaceuticals Corporation | — | Travel and Lodging | In-kind items and services | $171.35 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $792.80 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $174.93 | General |
| 08/17/2023 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $127.98 | General |
| 03/24/2023 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: Diabetes | ||||||
| 01/19/2023 | Siemens Medical Solutions USA, Inc. | MAGNETOM Altea (Device) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: MR - MRI | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Niclosamide | First Wave BioPharma, Inc. | $1.1M | 50 |
| ADAPTIVE PLATFORM TREATMENT TRIAL FOR OUTPATIENTS WITH COVID-19 | Eli Lilly and Company | $5,119 | 1 |
| Evaluation of SPN-812 ER 200 and 400 mg Efficacy and Safety in Children with ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial | Supernus Pharmaceuticals, Inc. | $1,568 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 143 | 278 | $33,970 | $19,085 |
| 2022 | 6 | 379 | 1,732 | $171,766 | $120,208 |
| 2021 | 7 | 469 | 2,193 | $201,701 | $149,145 |
| 2020 | 8 | 522 | 2,477 | $208,437 | $124,572 |
Total Patients
1,513
Total Services
6,680
Medicare Billing
$413,010
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 87 | 189 | $25,515 | $13,975 | 54.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 89 | $8,455 | $5,111 | 60.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 162 | 1,015 | $136,890 | $99,861 | 72.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 101 | 254 | $24,130 | $16,426 | 68.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $4,185 | $2,600 | 62.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 43 | 104 | $3,120 | $1,187 | 38.0% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2022 | 28 | 198 | $1,386 | $83.95 | 6.1% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 21 | 137 | $2,055 | $50.81 | 2.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 187 | 1,095 | $147,825 | $113,815 | 77.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 122 | 398 | $37,810 | $28,896 | 76.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 33 | 33 | $5,775 | $4,393 | 76.1% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 49 | 154 | $4,620 | $1,841 | 39.8% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2021 | 34 | 242 | $3,630 | $104.66 | 2.9% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2021 | 30 | 253 | $1,771 | $94.58 | 5.3% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2021 | 14 | 18 | $270.00 | $0.60 | 0.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 189 | 1,099 | $148,365 | $92,413 | 62.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 108 | 375 | $35,625 | $22,707 | 63.7% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 53 | 53 | $9,275 | $6,254 | 67.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 56 | 226 | $6,780 | $2,734 | 40.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2020 | 37 | 364 | $5,460 | $166.84 | 3.1% |
| 94640 | Respiratory inhaled pressure or nonpressure treatment to relieve airway obstruction or for sputum specimen | Office | 2020 | 17 | 20 | $200.00 | $157.92 | 79.0% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2020 | 35 | 296 | $2,072 | $137.99 | 6.7% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2020 | 27 | 44 | $660.00 | $1.37 | 0.2% |
About Dr. Keila Hoover, M.D
Dr. Keila Hoover, M.D is a Family Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417909375.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Keila Hoover, M.D has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $3,329 received in 2024. These payments were reported across 233 transactions from 41 companies. The most common payment nature is "" ($1.1M).
As a Medicare-enrolled provider, Hoover has provided services to 1,513 Medicare beneficiaries, totaling 6,680 services with total Medicare billing of $413,010. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Miami, FL
- Active Since 05/17/2006
- Last Updated 03/07/2023
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417909375
Products in Payments
- Dust mite (D. farinae) (Biological) $1,278
- Odactra (Biological) $724.52
- LAGEVRIO (Biological) $653.66
- TROKENDI XR (Drug) $182.53
- REVEAL LINQ (Device) $152.75
- Tresiba (Drug) $123.09
- Trulance (Drug) $109.20
- Vascepa (Drug) $68.66
- NEXPLANON (Drug) $64.07
- JATENZO (Drug) $47.97
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $42.59
- QULIPTA (Drug) $38.41
- SYMBICORT (Drug) $37.15
- Aimovig (Biological) $35.86
- Otezla (Drug) $35.61
- VRAYLAR (Drug) $31.72
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $30.73
- TRINTELLIX (Drug) $29.56
- INVOKANA (Drug) $28.80
- LEQVIO (Drug) $28.50
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Miami
Dr. Yamirka Duardo-Guerra, M.d, M.D
Family Medicine — Payments: $1.0M
Family Medicine $1.0M
Ramon Leon, Md, MD
Family Medicine — Payments: $179,798
Family Medicine $179,798
Mirel Sanchez, M.d, M.D
Family Medicine — Payments: $165,828
Family Medicine $165,828
Gilberto Seco, Md, MD
Family Medicine — Payments: $127,612
Family Medicine $127,612
Dr. Clifford Kinder, Md, MD
Family Medicine — Payments: $121,261
Family Medicine $121,261
Ana Elosegui, M.d, M.D
Family Medicine — Payments: $51,214
Family Medicine $51,214